Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome?

The antifungal agent terbinafine has been approved for marketing in The Netherlands since 1992. Adverse drug reactions (ADRs) may occur in about 10% of the patients, the majority gastrointestinal disorders and skin reactions. Since the introduction of terbinafine, the Netherlands Pharmacovigilance Foundation Lareb received eight reports of arthralgia during the use of this drug. In four reports the additional presence of skin reactions was mentioned, two of these reports concerned urticaria. Two patients who reported arthralgia also had a fever. These reports were described in more detail, and analysed statistically in order to determine whether symptoms are interrelated.

[1]  A. Egberts,et al.  Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs , 2000, European Journal of Clinical Pharmacology.

[2]  W. Stolz,et al.  Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine. , 1995, Archives of dermatology.

[3]  N. Shear,et al.  Hypersensitivity reaction to terbinafine. , 1997, Journal of the American Academy of Dermatology.

[4]  D. Bowen-Jones,et al.  Toxic epidermal necrolysis induced by terbinafine in a patient on long‐term anti‐epileptics , 1996, The British journal of dermatology.

[5]  S. Knowles,et al.  Serum Sickness—Like Reaction to Itraconazole , 1998, The Annals of pharmacotherapy.

[6]  Archer,et al.  Terbinafine‐induced acute generalized exanthematous pustulosis , 1998, The British journal of dermatology.

[7]  D. Golding.  Is There an Allergic Synovitis? , 1990, Journal of the Royal Society of Medicine.

[8]  N. Shear,et al.  Terbinafine: an update. , 1997, Journal of the American Academy of Dermatology.

[9]  T. Jones,et al.  Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses , 1989, Clinical and experimental dermatology.

[10]  J. Nethercott,et al.  Erythema multiforme (Stevens-Johnson syndrome)--chart review of 123 hospitalized patients. , 1985, Dermatologica.

[11]  B. Stricker,et al.  Serum sickness-like reactions to cefaclor. , 1992, Journal of clinical epidemiology.

[12]  J. McGregor,et al.  Terbinafine and erythema multiforme , 1994, The British journal of dermatology.

[13]  B. Bégaud,et al.  Is reporting rate a good predictor of risks associated with drugs? , 1999, British journal of clinical pharmacology.

[14]  S. Halpern,et al.  Oral terbinafine and erythema multiforme , 1995, Clinical and experimental dermatology.

[15]  A. Gupta,et al.  Hypersensitivity syndrome reaction to oral terbinafine , 1998, The Australasian journal of dermatology.

[16]  Broekmans Aw,et al.  Current regulations for reporting of side effects in The Netherlands after 1995 , 1996 .

[17]  Susan Holmes,et al.  Exacerbation of systemic lupus erythematosus induced by terbinafine , 1998, The British journal of dermatology.

[18]  Wilson,et al.  Correspondence. Severe pustular psoriasis provoked by oral terbinafine , 1998, The British journal of dermatology.

[19]  Murphy,et al.  Terbinafine‐induced lupus erythematosus , 1998, The British journal of dermatology.

[20]  Coulson,et al.  Terbinafine‐induced subacute cutaneous lupus erythematosus , 1998, The British journal of dermatology.

[21]  R. Meyboom,et al.  Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. , 1999, British journal of clinical pharmacology.

[22]  J. Jensen,et al.  Clinical pharmacokinetics of terbinafine (Lamisil) , 1989, Clinical and experimental dermatology.

[23]  L. Wilton,et al.  Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study , 1998, BMJ.

[24]  C. Needham,et al.  Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study. , 1996, British journal of clinical pharmacology.

[25]  R. Meyboom,et al.  Non-puerperal lactation associated with antidepressant drug use. , 2003, British journal of clinical pharmacology.

[26]  P. Krupp,et al.  Safety of oral terbinafine : Results of a postmarketing surveillance study in 25 884 Patients , 1997 .

[27]  N. Dupin,et al.  Acute generalized exanthematous pustulosis induced by terbinafine. , 1996, Archives of dermatology.

[28]  D. Faulds,et al.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. , 1992, Drugs.

[29]  M. Nahata,et al.  Oral Terbinafine: A New Antifungal Agent , 1997, The Annals of pharmacotherapy.

[30]  A. Quintela,et al.  Doxycycline-induced parotitis. , 1991 .

[31]  L. Juhlin.  Loss of taste and terbinafine , 1992, The Lancet.

[32]  F. Baudraz-Rosselet,et al.  Treatment of onychomycosis with terbinafine , 1992, The British journal of dermatology.

[33]  J. Ottervanger,et al.  Loss of taste and terbinafine , 1992, The Lancet.

[34]  M. Mockenhaupt,et al.  Stevens-Johnson syndrome after terbinafine therapy. , 1994, Journal of the American Academy of Dermatology.

[35]  K. thestrup-pedersen,et al.  Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. , 1994, Acta dermato-venereologica.

[36]  S. Knowles,et al.  Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. , 1997, Journal of the American Academy of Dermatology.